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Abstract
Antibiotic resistance is a growing health concern, and new avenues of antimicrobial drug design 
are being actively sought. One suggested pathway to be targeted for inhibitor design is that of iron 
scavenging through siderophores. Here we present a high throughput screen to the isochorismate-
pyruvate lyase of Pseudomonas aeruginosa, an enzyme required for the production of the 
siderophore pyochelin. Compounds identified in the screen are high nanomolar to low micromolar 
inhibitors of the enzyme and produce growth inhibition in PAO1 P. aeruginosa in the millimolar 
range under iron-limiting conditions. The identified compounds were also tested for enzymatic 
inhibition of E. coli chorismate mutase, a protein of similar fold and similar chemistry, and of Y. 
enterocolitica salicylate synthase, a protein of differing fold but catalyzing the same lyase 
reaction. In both cases, subsets of the inhibitors from the screen were found to be inhibitory to 
enzymatic activity (mutase or synthase) in the micromolar range and capable of growth inhibition 
in their respective organisms (E. coli or Y. enterocolitica).
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Most pathogens require iron for survival because this metal serves as a required cofactor in 
many essential biological processes including DNA biosynthesis and cellular respiration [1]. 
While direct mechanisms for iron uptake (for example, uptake of heme) have evolved, 
indirect methods of iron acquisition, such as the use of high affinity iron chelators called 
siderophores, allow for iron scavenging regardless of the source [1]. Siderophore 
biosynthesis has been linked to virulence in many pathogenic bacteria [2–10]: without the 
ability to scavenge iron from the host, the bacteria are incapable of causing disease. 
Salicylate-capped siderophores are produced by several pathogenic bacteria, such as 
Yersinia spp. including the causative agent of plague, Mycobacterium tuberculosis, which is 
the causative agent of tuberculosis, and Pseudomonas aeruginosa, a nosocomial pathogen 
infecting susceptible hosts, including burn victims, cancer patients with hematological 
malignancies and those undergoing chemotherapy, patients with immune deficiencies such 
as AIDS patients, and Cystic Fibrosis (CF) patients [11]. Compounds that prevent the 
formation of salicylate or its incorporation into siderophores may prove to be a new class of 
antimicrobial drugs in this age of antibiotic drug resistance.
P. aeruginosa, Yersinia spp., and M. tuberculosis make chemically related siderophores that 
all use a salicylate cap (Figure 1A), the hydroxyl group of which is involved in iron 
chelation [12]. The salicylate 2 is formed in two steps from chorismate 4 with an 
isochorismate 1 intermediate (Figure 1B). The first step is the general acid-general base 
isomerization of chorismate to form isochorismate [13–15], whereas the second is the 
pericyclic migration of the enolpyruvyl tail [15, 16]. Because the cyclic transition state for 
this reaction includes a hydrogen, the result is the elimination of the tail and the formation of 
salicylate and pyruvate 3. For Yersinia spp. (siderophore: yersiniabactin) and M. 
tuberculosis (mycobactin), both reactions are catalyzed by a salicylate synthase, Irp9 and 
MbtI, respectively. The generation of the siderophore pyochelin by P. aeruginosa requires 
two enzymes, an isochorismate synthase (PchA) and an isochorismate-pyruvate lyase 
(PchB). Interestingly, PchA, Irp9 and MbtI are all structural homologues in the MST 
(menaquinone, siderophore and tryptophan biosynthesis) family, but as yet it is unknown 
why PchA cannot perform the pericyclic lyase reaction [17]. There are homologues of PchA 
that are isochorismate synthases, which also cannot perform the pericyclic lyase reaction. E. 
coli MenF [18, 19] is involved in menaquinone biosynthesis whereas EntC [20–23] from E. 
coli and VibC [24, 25] from Vibrio cholera are found in the biosynthetic pathways for 
dihydroxybenzoate capped siderophores. For MenF, EntC and VibC, the inability to perform 
the lyase reaction is biologically logical, since isochorismate is required for the formation of 
the biosynthetic products whereas salicylate is not [17].
The current work was initiated as a high throughput screen for the isochorismate-pyruvate 
lyase from P. aeruginosa (PchB), which performs the second, pericyclic reaction in the 
generation of the pyochelin siderophore. PchB is easily generated, we have adopted an 
effective microbial production system for obtaining the substrate isochorismate [26], and the 
salicylate product is fluorescent, allowing for the development of an enzymatic assay 
suitable for automation. PchB is a structural homologue of E. coli chorismate mutase 
(EcCM) of the AroQ structural class (Figure 2) [27, 28]. EcCM is the N-terminal domain of 
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the well-studied bifunctional P-protein [29], the terminal enzyme of the shikimate 
biosynthetic pathway that is the branch point for the production of aromatic amino acids 
[30]. Both PchB and EcCM perform pericyclic reactions with similar transition states, 
differing in the alignment of the enolpyruvyl tail over the ring and thus the atomic 
composition of the cyclic transition state (Figure 2) [17]. The shikimate pathway is also 
recognized as an attractive target for antimicrobial drug design, since mammals do not 
synthesize aromatic amino acids. Rational design of inhibitors has been conducted for the 
chorismate mutases [31–38], including the TSA (transition state analogue), an oxabicyclic 
acid generated by Bartlett [34, 35]. EcCM is refractory to screening, because it lacks a good 
spectrophotometric handle and is difficult to make in sufficient quantities.
While pyochelin has been implicated in virulence [4, 10], any compounds that are effective 
inhibitors against PchB would need to be used in combination with inhibitors to the other 
iron scavenging pathways in P. aeruginosa, including that of the high affinity siderophore 
pyoverdin. Salicylate synthases (for example, Irp9 and MbtI mentioned above) perform the 
same pericyclic reaction as PchB (Figure 2), but are found in siderophore biosynthetic 
pathways necessary for virulence by organisms that are more limited in variety of iron 
uptake systems (most particularly, in Yersinia spp. [2, 3, 6] and M. tuberculosis [5, 7–9]). 
While salicylate synthases perform the same reaction, they do so using a different protein 
scaffold (Figure 2). Salicylate synthesis and activation of salicylate by adenylation for 
incorporation into siderophores have been the targets of inhibition studies to produce lead 
compounds for antimicrobial drug design. Rational design of inhibitors to enzymes such as 
isochorismate synthase, salicylate synthase and salicylate adenylase has been documented 
[39–59], as well as high throughput screening for inhibitors of salicylate synthase [60].
We hypothesized that compounds identified as inhibitors in an enzymatic screen may also be 
effective against an enzyme that performs the same chemistry albeit using a differing protein 
fold. By the same token, an inhibitor identified by screening methods may also be effective 
against a protein with a homologous protein scaffold and similar transition states, in this 
case, allowing for a way to identify inhibitors to an enzyme that is not suitable for screening. 
Therefore, we report a high-throughput screen designed to identify inhibitors of the 
isochorismate-pyruvate lyase from P. aeruginosa, measuring decreased salicylate 
production from isochorismate in the presence of an inhibitory compound. The compounds 
were further tested for inhibition of salicylate production from chorismate by the Y. 
enterocolitica salicylate synthase Irp9 which performs the same pericyclic lyase reaction but 
using a different protein fold. An orthogonal assay was used to measure inhibition of 
pyruvate production for both PchB and Irp9. Due to similarities in protein fold, substrate and 
transition state, identified compounds were also tested for inhibition of E. coli chorismate 
mutase activity, measuring chorismate disappearance. Finally, growth inhibition was 
measured for P. aeruginosa, E. coli and Y. enterocolitica for two of the most promising 
compounds.
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2.1 High Throughput Screen
Our assay measures the conversion of isochorismate to salicylate and pyruvate by the 
isochorismate-pyruvate lyase, PchB. The assay takes advantage of the fluorescent properties 
of salicylate, and is amenable to standard lab and high throughput conditions. Using the lab 
conditions and concentrations derived from steady state kinetics [27] as a starting point, a 
high-throughput assay was developed. Optimization of the assay conditions were tested by 
varying enzyme and substrate concentration and incubation times. The assay was insensitive 
to DMSO up to concentrations of 2%.
The assay was automated at the University of Kansas High Throughput Screening 
Laboratory and used to screen PchB versus the ChemDiv, ChemBridge, Microsource, 
Prestwick and the University of Kansas Chemical Methodologies and Library Development 
libraries. A pilot screen identified compound 6 as a positive control. Wells in each plate 
were reserved for no enzyme negative controls and 10 µM compound 6 positive controls to 
allow for the calculation of plate-to-plate statistics and to detect irregularities in the screen. 
Each compound was screened at a concentration of 10 µM. Substrate and enzyme dilutions 
were prepared fresh each day, with 30 plates run per day. Many compounds (258) were 
auto-fluorescent (showed > 100% inhibition) and were eliminated from further analysis 
(Supplemental Figure 1A). Compounds that showed inhibition effects greater than plate 
median plus three standard deviations but less than/equal to 100% (422 compounds) were 
deemed “actives” – a hit rate of 0.4%. Z’ factors on individual plates ranged from 0.5 to 0.9 
and was 0.8 overall (Supplemental Figure 1B). The signal to baseline ranged from 10 to 30. 
Active compounds (231 of the 422) were confirmed by rescreening from the source plates in 
the high-throughput assay. Based on score (IC50 values from dose response data), 
availability and price, five compounds from three structural classes (9–13) were purchased 
for further evaluation (Figure 3). Compounds 6–8 were no longer commercially available 
and so were synthesized as described in the Methods.
2.2 Inhibition of isochorismate-pyruvate lyase (PchB)
The eight selected hits from the high-throughput screen were more rigorously examined 
with the same conditions that were used to obtain the original kinetic constants [27]. Half 
maximal inhibitory concentration (IC50) values for the prospective inhibitors were 
calculated from dose response curves based on percent inhibition of PchB (Table 1). All 
compounds were effective with IC50 values ranging from 100 nM to 10 µM. KI values were 
determined for compounds 6, 9 and 10: 44 +/− 2 nM, 80 +/− 8 nM, and 350 +/− 40 nM, 
respectively, and all three were competitive inhibitors. An orthogonal assay was adopted to 
measure pyruvate production (as opposed to salicylate production) using an absorbance 
based assay. The calculated IC50 values for this assay were comparable to those from the 
original salicylate fluorescence assay.
2.3 Inhibition of salicylate synthase (Irp9)
Since Irp9 performs the same chemistry as PchB, albeit by an enzyme of a different 
structural class, the same assays (salicylate production and pyruvate production) were used 
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to determine IC50 values for the eight selected hits from the high-throughput screen. The 
compounds of the first structural class (6–8) were not inhibitory for Irp9 in either assay 
(Table 1). The remaining compounds showed IC50 values ranging from 25 to 160 µM in the 
salicylate production assay, but these values were only recapitulated in the pyruvate 
production assay for compounds 10 and 12. A KI value was determined for compound 10: 
0.8 +/− 0.2 µM, a competitive inhibitor.
2.4 Inhibition of chorismate mutase (EcCM)
EcCM and PchB are of the same structural class and both perform pericyclic reactions on 
similar substrates (chorismate and isochorismate). Therefore, the eight selected hits from the 
high-throughput screen were also tested for inhibition of EcCM using a chorismate 
disappearance absorbance assay. Compounds 6 through 13 gave IC50 values between 30 and 
200 µM (Table 1). KI values were determined for compounds 6 and 10: 30 +/− 10 µM, and 
40 +/− 20 µM, respectively, and both were competitive inhibitors.
2.5 Bacterial Growth Inhibition
To determine if the compounds were effective at inhibiting bacterial growth, half maximal 
effective concentration (EC50) values were determined for P. aeruginosa, Y. enterocolitica, 
and E. coli. The HTS and subsequent screens provided a minimal structure-activity 
relationship for the two compound classes represented by compounds 6 and 10. Therefore, 
these two compounds were chosen for EC50 determination. The EC50 values were 
determined in iron-rich (200 µM) or iron-poor (5 µM) media for both P. aeruginosa and Y. 
enterocolitica to determine if inhibition is related to iron uptake. The EC50 values were not 
determined in iron-free media, because the bacteria could not be reliably grown in the 
absence of iron even without potential inhibitors. For P. aeruginosa, EC50 values were 
determined for the wildtype PAO1 strain, for a pyoverdin-minus PAO1 strain, and for a 
pyochelin-minus PAO1 strain. The pyoverdin-minus strain is a ΔpvdA knockout strain, 
deficient in the ornithine hydroxylase enzyme that is the first committed step for production 
of the high-affinity pyoverdin siderophore. The pyochelin-minus strain is a ΔpchE knockout 
strain, deficient in the nonribosomal peptide synthetase required for salicylate incorporation. 
These data are normalized relative to bacteria grown in the absence of inhibitor and plotted 
as relative growth. The highest concentration of the compounds tested in these assays was 5 
mM, limited by solubility and vehicle (DMSO) toxicity.
Compounds 6 and 10 are sub-micromolar inhibitors of the isochorismate-pyruvate lyase 
required for pyochelin production. These compounds did not cause growth inhibition in 
iron-rich media, regardless of P. aeruginosa, strain (Figure 4A and 4B, Table 2). This was 
anticipated, since the bacteria were not reliant on siderophore production for iron uptake 
when the media is replete with iron. Under iron-limiting conditions, if the compounds were 
specific for inhibition of PchB, we would expect the strongest inhibition in pyoverdin-minus 
strain, as this strain is more reliant on the pyochelin pathway for iron-uptake. The wildtype 
PAO1 strain could show some growth inhibition or this could be overcome by the functional 
and more efficient pyoverdin pathway. The pyochelin-deficient strain should show no 
inhibition in relative growth, since the pyochelin production pathway was genetically 
disrupted. Both the wildtype PAO1 strain and the pyoverdin-minus strain showed growth 
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inhibition for both compounds at concentrations that were >5 mM. The pyochelin-minus 
strain was not inhibited by compound 6 but was inhibited at > 5mM by compound 10. These 
data suggest that compound 6 maybe more specific for the pyochelin pathway than 
compound 10. However, these data suggest that under iron-limiting conditions there may be 
a second target that is also inhibited by compound 10. P. aeruginosa has chorismate mutases 
that may be inhibited. Additionally, P. aeruginosa is highly antibiotic resistant due in part, 
to the presence of efflux pumps for the export of xenobiotics. Growth inhibition would 
likely be augmented in the presence of an efflux pump inhibitor, such as phenylalainine-
arginine-β-naphthylamide [61], a future direction of this work.
Compound 6 was not an enzymatic inhibitor of the Y. enterocolitica salicylate synthase Irp9, 
but compound 10 was a micromolar inhibitor. If our hypothesis was correct and compound 
10 was specific for yersiniabactin biosynthesis, then neither should inhibit Y. enterocolitica 
bacterial growth under iron rich conditions, and only compound 10 should inhibit under iron 
poor conditions. If the inhibitors are non-selective, then both may inhibit bacterial growth 
under both iron rich and iron poor conditions. If the inhibitors work against both the 
yersiniabactin biosynthesis and another enzymatic process, then compound 10 should be 
more effective under iron poor conditions. Based on the data in Figure 4C and Table 2, both 
compounds give EC50 concentrations in the millimolar range under both iron rich and iron 
poor conditions (indeed, the differing iron conditions were within error of each other), 
suggesting that compound 10 is not selective for siderophore biosynthesis and that both 
inhibitors are causing growth inhibition by some other mechanism.
Compounds 6 and 10 are low micromolar inhibitors of E. coli chorismate mutase. In growth 
inhibition assays against Seattle strain E. coli, compound 6 arguably showed no growth 
inhibition, while compound 10 gave an EC50 value of 3 mM (Figure 4D).
3. Discussion
Two inhibitors of PchB are reported in the literature: Bartlett’s TSA (Ki ~2 µM) and 
adamantane-1-phosphonate (Ki >5 mM) [62]. The work reported here identifies three 
compounds with Ki values in the nanomolar range: 6 (Ki 44 +/− 2 nM), 9 (Ki = 80 +/− 8 nM) 
and 10 (Ki = 350 +/− 40 nM). In addition, compounds 6 and 10 show growth inhibition of P. 
aeruginosa at millimolar concentrations under iron-limiting conditions. Therefore, these 
compounds represent the best known inhibitors of PchB, and may serve as initial lead 
compounds for the development of new antibtiotics.
To our knowledge, the best known inhibitor for E. coli chorismate mutase is Bartlett’s TSA. 
The literature reports inhibition of this and similar compounds as I50/Km1, with a value of 
0.008 for the TSA [34, 35]. Similar calculations were performed for compounds 6 and 10 
versus EcCM, and values of 0.05 and 0.053 were determined, better than all of the reported 
compounds save the TSA. These compounds therefore represent new scaffolds suitable for 
1Bartlett and colleagues reported inhibition of chorismate mutase/prephenate dehydrogenase by their transition state analogues as 
I50 /Km values [34, 35], where they defined I50 as “the concentration of inhibitor giving 50% inhibition when the substrate 
concentration equals Km” [34]. For the sake of direct comparison, we likewise make these calculations.
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optimization as chemical probes and inhibitors of chorismate mutases. Furthermore, 
compound 10 also was effective at growth inhibition of E. coli in the millimolar range.
Rational design of inhibitors against isochorismate and salicylate synthases and similar 
chorismate-utilizing enzymes have primarily targeted varying the pyruvylenol tail of the 
substrate and have produced inhibitors with low micromolar Ki values [47, 51, 52, 63] 
Interestingly, in two cases, PchB was used to convert isochorismate generated by an 
isochorismate synthase into salicylate for detection but there is no mention as to whether the 
inhibitors were tested for inhibition of PchB alone [51, 52]. A high-throughput screen 
against the salicylate synthase from M. tuberculosis (MbtI) identified two structural classes 
of inhibitors, which showed IC50 values in the low micromolar range [60]. The first was a 
diarylsulfone reminiscent of compound 9; however, compounds of this scaffold have been 
identified as pan assay interference compounds [64] and are therefore unlikely for further 
development. The second was a benzimidazole-2-thione similar to compounds 10–12. We 
likewise determined a micromolar IC50 values for compound 10 with the Y. enterocolitica 
salicylate synthase Irp9, which shows growth inhibition of Y. enterocolitica in the low 
millimolar range. These fused heterocyclic ring systems may be an excellent starting point 
for inhibition in the MST enzyme class.
We hypothesized that an inhibitor identified through a high throughput screen may be 
effective against enzymes of similar scaffold or the same catalytic function. The screen 
against the isochorismate-pyruvate lyase identified competitive inhibitors that were found to 
likewise be competitive inhibitors against chorismate mutase (similar fold and active site 
structure) and salicylate synthase (same catalytic mechanism). While one may speculate that 
the ability to “target hop” may be only possible with competitive inhibitors, exploiting 
similarity of the active site and/or transition state, it is also possible to envision a scenario 
where an allosteric regulator binding site may also be similarly employed. The bacterial 
inhibition studies suggest that the compounds may be multi-selective. In other words, the 
compounds inhibit proteins of similar structure and/or function in vitro, and may do so in 
vivo as well. All of the bacterial cultures grown generate chemically-related siderophores 
with salicylate or dihydroxybenzoate caps utilizing enzymes that are structurally or 
functionally related the PchB and/or Irp9. These bacterial species also produce aromatic 
amino acids, thereby utilizing a chorismate mutase of the same structural family as EcCM. 
However, these studies do not rule out the possibility that these inhibitors are non-selective, 
inhibiting a target dissimilar and completely independent to those tested. Identification of 
the cellular target(s) is the next important step in this experimentation. .
4. Conclusions
The HTS screen presented here identified inhibitors of the isochorismate-pyruvate lyase 
from P. aeruginosa. Lead compounds were scrutinized in an orthogonal assay and for 
bacterial growth inhibition. The inhibitors were similarly tested against an enzyme that 
performs identical chemistry in a different protein scaffold (salicylate synthase) and against 
an enzyme with a homologous protein scaffold that performs similar chemistry (chorismate 
mutase). Inhibitors were identified that are better than those previously reported in the 
literature, and also cause growth inhibition of P. aeruginosa in a seemingly iron-dependent 
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way. A subset of the identified inhibitors were also effective against enzymes of similar 
scaffold (EcCM) or identical chemistry (Irp9). The result is a series of compounds are 
among the most effective inhibitors to date for all three enzymes and may prove useful in 
the discovery of future antibiotics.
5. Methods
5.1 Preparation of substrates
Isochorismate was isolated from Klebsiella pneumoniae 62-1 harboring the entC plasmid 
pKS3-02 [26] with only minor changes, as described previously [27]. Chorismate was 
isolated from Klebisella pneumonia 62-1 [65] with only minor changes, as previously 
described [14].
5.2 Preparation of Overexpression Plasmids
The PchB overexpression plasmid (without a histidine tag) was generated as previously 
described [28]. The Irp9 overexpression plasmid was generated as previously described [66].
E. coli chorismate mutase (EcCM) is a domain of a larger pheA gene. The EcCM domain 
portion of the pheA gene was amplified from Escherichia coli K-12 substrain genomic 
MG1655 DNA (ATCC) by polymerase chain reaction by use of Master Mix (Eppendorf) 
with 1.5 mM magnesium acetate. The forward primer (5’-ATC GTC ATA TGA CAT CGG 
AAA ACC CGT TA-3’) includes an NdeI site (underlined) and the reverse primer (5’-TTA 
AGC TTT CAG AGA AAA GCG ATG CGT GCT G-3’) contains a stop codon and a 
HindIII site (underlined). The amplified 352 base pair fragment was digested with NdeI and 
HindIII and ligated into the pET28b plasmid (Novagen) digested with the same enzymes. 
The resultant plasmid encodes the chorismate mutase domain of pheA with an N-terminal 
histidine tag and no mutations.
5.3 Protein overexpression and purification
PchB without the histidine tag was overexpressed and purified as previously described [28]. 
Irp9 was overexpressed and purified as previously described [66].
BL21 Star (DE3) pLysS E. coli containing the EcCM expression plasmid were grown in LB 
medium containing 50 µg/mL kanamycin at 37 °C with shaking (250 rpm) until an OD600 of 
~0.8 was reached. The culture temperature was reduced to 30 °C and the cells were 
harvested by centrifugation (6 000g, 10 min, 4 °C) after 4 h. The cell pellet was resuspended 
in 15 mL of 20 mM Tris-HCl pH 8.8, 500 mM NaCl, 5 mM imidazole (buffer A) per liter of 
culture. Cells were disrupted by use of a French pressure cell (35 000 psi), and cellular 
debris was removed by centrifugation (12 000g, 30 min, 4 °C). The supernatant was applied 
to a chelating Sepharose fast-flow column (Amersham Biosciences) charged with nickel 
chloride and pre-equilibrated in buffer A. EcCM protein eluted at 250 mM imidazole in a 
linear gradient of 5–500 mM imidazole in buffer A. The pooled fractions were applied to a 
Superdex 75 size-exclusion column (Amersham Biosciences) equilibrated with 25 mM 
sodium phosphate pH 8.5, 150 mM KCl, 10% glycerol. The fractions containing EcCM 
were pooled and concentrated by use of an Amicon stirred cell with a YM-10 membrane to 
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417 µM as determined by absorbance at 280 nm (ext. coeff 1,490 M−1 cm−1) and stored at 
−80 °C.
5.4 High-throughput screening
To identify inhibitors of PchB required for salicylate synthesis, high throughput screening 
was performed using an assay in which isochorismate is converted to salicylate by PchB. 
The fluorescence of salicylate was measured with an excitation wavelength of 300 nm and 
an emission wavelength of 400 nm. The assay was adapted to 384-well (Costar #3575) 
format and used to screen the compound libraries available at the University of Kansas High 
Throughput Screening Laboratory, Lawrence, Kansas. The compound collection was 
derived from both commercially available compound libraries (Prestwick (1120 
compounds), Microsource Spectrum collection (2000 compounds), ChemDiv library (50,000 
compounds), Chembridge library (43,736 compounds)) and the compounds (3360) 
synthesized at the University of Kansas Center for Chemical Methodologies and Library 
Development (CMLD). All enzyme and substrate stocks were prepared in reaction buffer 
containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM TCEP. The assay was 
initiated by adding PchB (12 nM final concentration) enzyme mixture to compounds (10 µM 
final concentrations) in a 384-well plate and incubated 5 mins at room temperature. The 
reaction was initiated by adding substrate (isochorismate, 3 µM final which is 1.5-times the 
Km) solution to the wells containing the compounds and enzyme mixture. The fluorescence 
intensity was measured at 0 and 20 mins, during which time the reaction was linear at 25 °C, 
using a Tecan Safire2 plate reader. Each plate had 16 wells of positive controls (DMSO with 
no compound) and 14 wells for minus protein negative controls. A compound identified 
from a previous ChemBridge library screen (ChemBridge #5325243) was included in two 
wells as a positive assay control (6 µM). In summary, a total number of 100,216 compounds 
were screened.
5.5 HTS data analysis
Relative Fluorescence Units (RFU) per minute was calculated by subtracting the 
fluorescence intensity from pre-reads (before the addition of isochorismate) from that of the 
end reads (20 mins after the addition of isochorismate). The percent inhibition was 
calculated from median RFU/min in all DMSO/compound containing wells. A hit rate of 
0.4% was obtained with 422 compounds showing >50% inhibition in salicylate synthesis 
over the DMSO treated controls. An average Z’ value of 0.80 ± 0.05 was obtained across all 
plates screened.
5.6 Secondary screening at HTS facility
All 422 compounds were cherry picked and tested for activity in an 8-point dose-response 
curve with 2-fold serial dilutions starting at 30 µM. The primary screening assay was used to 
confirm activity of the cherry-picked compounds. A reconfirmation rate of 50% was 
obtained and 131 compounds were found to be dose-responsive, with IC50 values ranging 
from 410 nM to >30 µM.
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5.7 Preparation of compounds for confirmatory assays and minimum inhibitory 
concentration
Compounds 9–13 were purchased from ChemDiv. Compounds 6, 7, and 8 were no longer 
available from ChemBridge and were prepared by a modified procedure that was originally 
reported by Miller and colleagues [67].
5.7.1 General procedure—Anthranilic acid (177 mg, 1.29 mmol) was added to a 
solution of Na2CO3 (5 mL, 0.63 M) at 60°C. The appropriate sulfonyl chloride (1.55 mmol, 
1.2 equiv) was added in three portions over a period of 10 min. The reaction was heated to 
75°C for 30 min and then raised to 85°C and quenched with a solution of HCl (1 mL, 6 M). 
The solution was cooled to room temperature and the resulting precipitate collected by 
vacuum filtration and was dried under vacuum overnight. All materials were obtained from 
commercial suppliers and used without further purification. 1H NMR and 13C NMR were 
recorded on a Bruker AV-500 with cryoprobe. Chemical shifts (δ) are reported in ppm 
downfield from TMS and are referenced to the residual DMSO solvent peak. High 
resolution mass spectroscopy (HRMS) was performed using a LCT Premier (Micromass 
Ltd., Manchester UK) time of flight mass spectrometer with an electrospray ion source. 
Melting points are uncorrected and were measured on a Thomas Hoover Capillary Melting 
Point Apparatus.
5.7.2 5-(N-(2-carboxyphenyl)sulfamoyl)-2-hydroxybenzoic acid (Compound 6)
—1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.14 (d, J = 2.5 Hz, 1H), 7.89 (dd, J = 7.9, 
1.5 Hz, 1H), 7.84 (dd, J = 8.8, 2.5 Hz, 1H), 7.57 (m, 1H), 7.49 (dd, J = 8.3, 0.9 Hz, 1H), 
7.14 (td, J = 8.0, 1.2 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
170.19, 169.76, 164.32, 139.62, 134.63, 133.47, 131.64, 130.06, 128.84, 123.78, 119.07, 
118.66, 117.30, 113.97. HRMS: [M-H]− calcd 336.0178, found 336.0183. Melting point: 
221–222°C (dec.)
5.7.3 2-(3-carboxyphenylsulfonamido)benzoic acid (Compound 7)—1H NMR 
(500 MHz, DMSO) δ 11.21 (s, 1H), 8.26 (t, J = 1.6 Hz, 1H), 8.15 (m, 1H), 8.02 (ddd, J = 
7.9, 2.0, 1.1 Hz, 1H), 7.88 (dd, J = 7.9, 1.5 Hz, 1H), 7.69 (dd, J = 11.8, 4.0 Hz, 1H), 7.57 
(m, 1H), 7.50 (dd, J = 8.3, 0.9 Hz, 1H), 7.15 (td, J = 7.9, 1.2 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 169.68, 165.77, 139.33, 139.20, 134.58, 134.04, 132.03, 131.62, 130.91, 130.33, 
127.31, 123.97, 119.24, 117.65. HRMS: [M-H]− calcd 320.0229 found 320.0229. Melting 
point: 234–236°C (dec.)
5.7.4 2-bromo-5-(N-(2-carboxyphenyl)sulfamoyl)benzoic acid (Compound 8)
—1H NMR (500 MHz, DMSO) δ 11.16 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.91 (t, J = 8.4 Hz, 
1H), 7.90 (s, 1H), 7.80 (dd, J = 8.4, 2.4 Hz, 1H), 7.57 (ddd, J = 8.5, 7.4, 1.6 Hz, 1H), 7.47 
(dd, J = 8.3, 0.8 Hz, 1H), 7.17 (td, J = 7.9, 1.1 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
169.59, 165.85, 138.99, 138.25, 135.53, 134.61, 134.58, 131.68, 130.25, 128.73, 126.01, 
124.10, 119.30, 117.84. HRMS: [M-H]−calcd 397.9334, found 397.9333. Melting point: 
219–220°C (dec.)
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5.8 Salicylate fluorescence assay
For the PchB assays, 50 nM enzyme was added to 50 mM potassium phosphate, pH 8 and 
the reaction was initiated by the addition of isochorismate. For the Irp9 assays, 100 nM 
enzyme was added to 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 10% (v/v) glycerol and the 
reaction was initiated by the addition of chorismate. Initial velocities were determined at 25 
°C by measuring the accumulation of salicylate by fluorescence with an excitation 
wavelength of 310 nm and an emission wavelength of 430 nm using a Cary Eclipse 
fluorescence spectrometer (Varian) with temperature controller. Initial velocities were 
measured for 120 seconds during which the reaction was linear. The substrate concentration 
was set at the Km of 2 µM for IC50 determination, and the inhibitor concentrations varied. 
For the Ki determination for compounds 9 and 10, the PchB concentration was 50 nM and 
the isochorismate concentrations ranged from 0–75 µM with inhibitor concentrations 
ranging from 0–100 nM for compound 9 and 0–1.5 µM for compound 10. The data was 
collected as for the IC50 determination measuring the fluorescence of salicylate at 430 nm 
upon excitation at 310 nm.
The Ki was determined for compound 6 using a TgK Scientific SF-61DX2 stopped-flow 
apparatus equipped with a photomuliplier detector and a mercury-xenon lamp at 25 °C. 
Equal volumes of enzyme with inhibitor were mixed with isochorismate (for PchB Ki 
determination) or chorismate (for Irp9 Ki determination) and initial velocity measurements 
were collected as an increase in salicylate fluorescence upon excitation at 310 nm using a 
cutoff filter at 360 nm. Initial velocities determined using the stopped-flow were measured 
for 30 seconds during which the reaction was linear. The final concentration of PchB was 50 
nM, the isochorismate concentration ranged from 0–50 µM and the inhibitor concentration 
ranged from 0–100 nM in a reaction buffer of 50 mM potassium phosphate, pH 8, 1 mM 
TCEP. The final concentration of Irp9 was 100 nM, the chorismate concentration ranged 
from 0–40 µM and the inhibitor concentration ranged from 0–10 µM in a reaction buffer of 
50 mM Tris, pH 7.5, 10 mM MgCl2, 10% glycerol.
5.9 Pyruvate production assay
This assay is based on the method described by Anthon and Barrett [68]. For the PchB 
pyruvate production assays, 50 nM enzyme was added to 50 mM potassium phosphate, pH 8 
and the reaction was initiated by the addition of isochorismate. For Irp9, 200 nM enzyme 
was used and the reaction was initiated by the addition of chorismate. Initial velocities were 
determined at 25 °C by adding 70 µl of sample at 2 min time points to 70 µl 0.25 g/L 2,4-
dinitrophenylhydrazine in 1 M HCl and incubated 10 min at 37 °C. The absorbance at 515 
nm was read upon addition of 70 µl 1.5 M NaOH using a Cary 50 MPR microplate reader 
(Varian) and converted to pyruvate concentration by means of a standard curve. The 
substrate concentration was set above the Km of 10 µM for IC50 determination, and the 
inhibitor concentrations varied. All experiments were performed in triplicate.
5.10 Chorismate disappearance assay
For the EcCM assays, the disappearance of chorismate was determined using a TgK 
Scientific SF-61DX2 stopped-flow apparatus equipped with a photomuliplier detector and a 
mercury-xenon lamp operated at 37 °C. Equal volumes of enzyme with inhibitor were mixed 
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with chorismate in reaction buffer consisting of 50 mM Tris-HCl, pH 8, 2.5 mM EDTA, 20 
mM βME, 0.01 % BSA and initial velocity measurements were collected as a decrease in 
absorbance at 310 nm for 30 seconds during which the reaction was linear. Pre-injection 
enzyme, substrate, and inhibitor concentration were twice the final concentration in the cell 
(post-mixing). The post-mixing concentrations were 500 nM for the enzyme, substrate 
chorismate concentration was set at the Km of 600 µM, and the inhibitor concentration 
varied from 0–500 µM. All experiments were performed in triplicate. For the Ki 
determination of compounds 6 and 10, the final concentration of EcCM was 500 nM, the 
chorismate concentration ranged from 0–2 mM and the inhibitor concentration ranged from 
0–50 µM.
5.11 Bacterial strains used for growth inhibition assays
Wild type strains include E. coli strain Seattle (ATCC, 25922), Yersinia enterocolitica 
(ATCC 9610) and P. aeruginosa PAO1 (provided by Dr. Jeffrey L. Urbauer, University of 
Georgia, Athens, GA). P. aeruginosa deletion mutant strains were acquired from a P. 
aeruginosa PAO1 transposon mutant library (University of Washington [69]) and include a 
P. aeruginosa PAO1 PvdA deletion mutant (PW5011) and a P. aeruginosa PAO1 PchE 
deletion mutant (PW8175).
5.12 Growth inhibition assasy
P. aeruginosa and Y. enterocoltica were grown overnight in LB media and diluted to an 
OD600 of 0.5 with PMH-D media [70]. Dose response curves were determined by adding 10 
µl diluted cells with 90 µl of PMH-D media with 5 µM FeCl3 (iron-limited) or 200 µM 
FeCl3 (iron-rich) containing inhibitor concentrations of 0–5 mM. The plates were incubated 
at 37 °C with shaking (200 rpm) for 24 hrs at which time the well solution was centrifuged 
to pellet the cells and the media with residual inhibitor was removed. The cells were 
resuspended in 100 µl LB media and the absorbance at 600 nm was read using a Cary 50 
MPR microplate reader (Varian). E. coli were grown overnight in LB media and diluted to 
an OD600 of 0.2 with LB media. Dose response curves were determined by adding 10 µl 
diluted cells with 90 µl of tryptic soy broth containing inhibitor concentrations of 0–5 mM. 
The plates were incubated at 37 °C with shaking (200 rpm) for 10 hrs and the absorbance 
was read at 600 nm. All experiments were performed in triplicate.
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EcCM E. coli chorismate mutase
EntC isochorismate synthase from E. coli
Irp9 salicylate synthase from Yersinia enterocolitica
MbtI salicylate synthase from Mycobacterium tuberculosis
MenF isochorismate synthase from E. coli
MST protein family containing proteins of menaquinone, siderophore or tryptophan 
biosynthesis
PchA isochorismate synthase from Pseudomonas aeruginosa
PchB isochorismate-pyruvate lyase from Pseudomonas aeruginosa
TSA transition state analogue
VibC isochorismate synthase from Vibrio cholera
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Figure 1. Salicylate-capped Siderophores and the Enzymes Targeted
a. The salicylate-capped siderophores generated by P. aeruginosa (pyochelin), Yersinia spp. 
(yersiniabactin) and M. tuberculosis (mycobactin). b. The isochorismate-pyruvate lyase 
from Pseudomonas aeruginosa (PchB) is the specific enzyme of screen, and performs the 
pericyclic cleavage of isochorismate 1 to form salicylate 2 and pyruvate 3. Inhibitors were 
also tested against the salicylate synthase from Yersinia enterocolitica (Irp9), which is a 
chorismate-utilizing enzyme and a structural homologue of the isochorismate synthase PchA 
from P. aeruginosa. Irp9 and PchA catalyze the conversion of chorismate 4 to isochorismate 
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1. Irp9 subsequently catalyzes the same lyase reaction as PchB from an isochorismate 
intermediate, whereas PchA does not. The compounds were also tested for inhibition of E. 
coli chorismate mutase (EcCM), also a chorismate-utilizing enzyme, which performs a 
pericyclic reaction similar to that catalyzed by PchB, generating prephenate 5.
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Figure 2. Enzyme scaffolds and transition states
The X-ray crystallographic structures for PchB (PBD code: 3REM) with salicylate and 
pyruvate bound, EcCM (1ECM) with Bartlett’s TSA inhibitor bound, and Irp9 (2FN1) with 
Mg2+, salicylate and pyruvate are depicted as cartoons. Each of these enzymes is a 
homodimer, with one monomer shaded darker than the other, and the active sites identified 
by the ligands shown as sticks. PchB and EcCM share the same fold – they are AroQ 
enzymes, whereas Irp9 is in the MST family of enzymes. The transition states for the 
reactions catalyzed, isochorismate-pyruvate lyase (left) and chorismate mutase (right), are 
shown below. The transition states are similar, differing only in the alignment of the 
pyruvylenol tail over the ring to make a cycle at the 1 (mutase) or 2 (lyase) carbon. PchB 
and Irp9 perform the same chemistry using different scaffolds, whereas PchB and EcCM 
perform related reactions in the same scaffold. It should be noted that PchB has adventitious 
mutase activity, albeit very low.
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Figure 3. Compounds selected from screen for further evaluation
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Figure 4. Growth inhibition of Pseudomonas aeruginosa, Yersinia enterocolitica and E. coli 
growth
a. P. aeurginosa growth inhibition by compound 6. b. P. aeurginosa growth inhibition by 
compound 10. For both A and B, left: WT PAO1 strain; middle: ΔpvdA PAO1, a pyoverdin 
minus strain; right: ΔpchE PAO1, a pyochelin minus strain. c. Y. enterocolitica growth 
inhibition by compound 6 (left) and compound 10 (right). For A–C: symbols: ∘ iron poor, ∙ 
iron rich. d. E. coli growth inhibition by compound 6 (∘) and compound 10 (∙) under iron 
rich conditions.
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